ライフサイエンスコーパス: countermeasure

1 tial therapeutic agents and vaccine (medical countermeasures).

2 n information campaign might be an effective countermeasure.

3 V-1 overcame this obstacle by using Vpu as a countermeasure.

4 uture development of a pan-filovirus medical countermeasure.

5 on of the pharmacodynamics of this radiation countermeasure.

6 ht therapy and the use of light as a fatigue countermeasure.

7 it may support use as a holistic spaceflight countermeasure.

8 has been proposed as a holistic spaceflight countermeasure.

9 the role of vaccines as the most attractive countermeasure.

10 ld provide an additional adjunct therapeutic countermeasure.

11 l models is essential for evaluating medical countermeasures.

12 for aerosol spread and the lack of existing countermeasures.

13 ng COVID-19 pathogenesis and testing medical countermeasures.

14 ses and the timely activation of appropriate countermeasures.

15 primate SAMHD1 has coevolved to evade these countermeasures.

16 ing challenges in devising effective medical countermeasures.

17 (EBOV) infection is paramount for developing countermeasures.

18 of or after treatment with candidate medical countermeasures.

19 ers cooperation in the absence of additional countermeasures.

20 pathology and as a possible target for novel countermeasures.

21 for various applications including infrared countermeasures.

22 microbial resistance (AMR) demands immediate countermeasures.

23 o better model disease and develop antiviral countermeasures.

24 ion genetics of a drive and proposed genetic countermeasures.

25 sis models for the rapid testing of possible countermeasures.

26 virions and for developing related antiviral countermeasures.

27 free space communications, and illuminators/countermeasures.

28 eed for research aimed at developing medical countermeasures.

29 DA approved pharmaceutical agents or medical countermeasures.

30 logy is desperately needed to develop better countermeasures.

31 Efficacy of drive reversal varies between countermeasures.

32 virus, underscoring the need for efficacious countermeasures.

33 yelitis for the development of novel medical countermeasures.

34 elopment of effective therapeutics and viral countermeasures.

35 ther to rapidly develop vaccine and antibody countermeasures.

36 virus transmission is critical to developing countermeasures.

37 id in the development and testing of medical countermeasures.

38 tion are needed as early screens for medical countermeasures.

39 the ensuing damage by responding with immune countermeasures.

40 bility to investigate this virus and develop countermeasures.

41 kers can design and implement more effective countermeasures.

42 of L- and S-tetherins to primate lentiviral countermeasures.

43 of RVF and to use for evaluation of medical countermeasures.

44 remarkable diversity of immune responses and countermeasures.

45 r ability to study Ebola viruses and develop countermeasures.

46 s animal model for testing candidate medical countermeasures.

47 anding pathogenesis and developing effective countermeasures.

48 ceivers to confound the deception test using countermeasures.

49 ) mice an excellent choice to assess medical countermeasures.

50 eployment of novel and potent anti-infective countermeasures.

51 pathways against which viruses have evolved countermeasures.

52 nt, production and distribution of effective countermeasures.

53 the pathogenesis of melioidosis and medical countermeasures.

54 immune response to serve as potential viral countermeasures.

55 key reagents to study SARS-CoV-2 and develop countermeasures.

56 ol spread and the current lack of sufficient countermeasures.

57 apid development of vaccines and therapeutic countermeasures.

58 tems for studying this virus and identifying countermeasures.

59 ity rate, epidemic potential, and no medical countermeasures.

60 disease and test immune and antiviral-based countermeasures.

61 ovide alternative strategies to the existing countermeasures.

62 egarding the quantitative data and effective countermeasures.

63 -vitro experiments to quickly assess medical countermeasures.

64 procedures to ascertain efficacy of medical countermeasures.

65 hout reducing progress in the development of countermeasures.

66 ion via TRAIL in the absence of m166-imposed countermeasures.

67 ponse, and consequently viruses have evolved countermeasures.

68 dity, and ethics of clinical studies of such countermeasures?

69 ded urgently for rapid evaluation of medical countermeasures(2,3).

70 hat hemoadsorption with CS could be a viable countermeasure against acute mycotoxin exposure.

71 Vaccines are still the best countermeasure against emerging influenza virus infectio

72 ng the potential development of BCX4430 as a countermeasure against human filovirus diseases and othe

73 Vaccines are the best available countermeasure against infection, but vaccine effectiven

74 influenza vaccines are the major preventive countermeasure against influenza virus.

75 Although vaccination is a major countermeasure against influenza, current vaccines are n

76 k during non-epidemic periods or as an early countermeasure against nascent outbreaks could therefore

77 tion of nano-OPH as a catalytic bioscavenger countermeasure against organophosphorus chemical warfare

78 anti-ceramide therapeutics and an effective countermeasure against radiation GI syndrome mortality.

79 e tested the effect of different lights as a countermeasure against sleep-loss decrements in alertnes

80 te that targeting this pathway may provide a countermeasure against the damaging effects of IR exposu

81 upplementation with DP could be an effective countermeasure against the skeletal deficits observed in

82 t of lipid-nanoparticle-delivered siRNA as a countermeasure against this highly lethal human disease.

83 Thus, development of more effective countermeasures against acute organophosphorus poisoning

84 nly used to evaluate the efficacy of medical countermeasures against anthrax in support of licensure

85 aid development and evaluation of effective countermeasures against Ebola.

86 hould not be neglected in the development of countermeasures against ebolaviruses.

87 ironments, which will aid the development of countermeasures against EBOV infection.

88 tagonists may serve as a possible target for countermeasures against HAND.

89 r structure should inform rational design of countermeasures against HCMV, other herpesviruses, and e

90 an be harnessed for development of effective countermeasures against henipavirus disease.

91 ntegrates redox signals to regulate specific countermeasures against host defense.

92 ivo conditions indicated that many bacterial countermeasures against host defenses remain critical fo

93 erating the development of effective medical countermeasures against human MHF.

94 Despite countermeasures against influenza virus that prevent (va

95 Countermeasures against JUNV infection are limited to im

96 , ciprofloxacin is part of the first-line of countermeasures against numerous high consequence bacter

97 used as a platform for delivering biological countermeasures against pandemic and biological threats.

98 The rapid development of effective medical countermeasures against potential biological threat agen

99 Countermeasures against potential biothreat agents remai

100 herapy, as well as more rapid development of countermeasures against potential biothreats.

101 Currently, there are no prophylactic countermeasures against radiation GI syndrome lethality

102 may offer a new avenue in the development of countermeasures against ricin toxin.toxin, antibody, str

103 e way for novel therapeutic and prophylactic countermeasures against SSTI.

104 Unfortunately, proposed countermeasures against such attacks have failed to be e

105 Although viral countermeasures against tetherin can differ significantl

106 Effective countermeasures against the recent emergence and rapid e

107 opportunities to design appropriate medical countermeasures against them.

108 d is therefore one of the primary targets of countermeasures against these dangerous infectious agent

109 Effective countermeasures against these viruses are highly desired

110 esis of SFTS is crucial to improving medical countermeasures against this devastating disease.

111 likely to be appropriate for testing medical countermeasures against this EBOV-Makona stock but may p

112 In order to develop countermeasures against this severe disease, animal mode

113 d to develop and license appropriate medical countermeasures against this virus.

114 dynamics are limiting factors for developing countermeasures against this virus.

115 t adverse effects reveals a viable radiation countermeasures agent.

116 However, for an evaluation of medical countermeasures, AGMs appear to be a more appropriate mo

117 nstrated its efficacy both as a prophylactic countermeasure and a mitigator in CD2F1 mice exposed to

118 Vaccines are an essential countermeasure and are urgently needed to control the pa

119 dicate that CDX-301 is a promising radiation countermeasure and demonstrate its capability to protect

120 There is one reported pharmaceutical countermeasure and it is vital that this medicine be fur

121 accelerate the development of effective ZIKV countermeasures and increase our preparedness against th

122 Hypotensive episodes can be managed with countermeasures and short-acting pressor agents if neces

123 oneer exciting new breakthroughs in security countermeasures and suicide prevention.

124 that BatA is a target for developing medical countermeasures and that vaccination with a mutant lacki

125 manent damage, but if we spend large sums on countermeasures and the problem turns out to be minor or

126 correlates of protection for antibody-based countermeasures and vaccines against SARS-CoV-2.

127 ent a novel lethal model for studies of CCHF countermeasures, and CCHF-associated CNS disease.

128 shift nurses' perceptions of drowsy driving, countermeasures, and educational and technological inter

129 s used to assess early transmission, medical countermeasures, and evolution of Ebola virus.

130 to mechanisms of host innate immunity, viral countermeasures, and the evolutionary interplay between

131 ir high mortality rates, the lack of medical countermeasures, and their potential use as instruments

132 ing results, and availability of an approved countermeasure appears to be close.

133 Optical glare countermeasures are available for daytime driving but no

134 eness of the sperm and the associated female countermeasures are not precisely matched.

135 y in self-correction: Whereas the claim that countermeasures are sufficient is always subject to corr

136 this model, potential obstacles, and related countermeasures, as well as future perspectives for its

137 a global research effort to identify medical countermeasures at an unprecedented pace.

138 r threat to global health(1) and the medical countermeasures available so far are limited(2,3).

139 As a countermeasure, bacterial pathogens have evolved mechani

140 we describe the use of a promising radiation countermeasure, BBT-059, and the results of a long term

141 e HAI outbreaks help practitioners implement countermeasures before the infection spreads extensively

142 zole aldoximes allows the design of a new OP countermeasure by conversion of hBChE from a stoichiomet

143 The countermeasure by influenza B virus is unique in that it

144 The choice among countermeasures by researchers and regulators will depen

145 opriate biomarkers for early diagnosis, thus countermeasure can be taken.

146 of released individuals containing a genetic countermeasure can substantially impact outcomes.

147 was to estimate the effects of body size and countermeasure (CM) exercise in an all-male crew compose

148 Importantly, therapeutic countermeasures comprising MERS-CoV neutralizing antibod

149 race between prey and predator, measures and countermeasures continuously evolve to increase survival

150 severe hemorrhagic fevers in humans, with no countermeasures currently being available, and must be s

151 to evaluate the efficacy of several specific countermeasures developed through years of preclinical w

152 avirus infection and provide new avenues for countermeasure development against pathogenic bunyavirus

153 ging of infectious disease processes may aid countermeasure development and lead to an improved under

154 Rapid SARS-CoV-2 countermeasure development is contingent on the availabi

155 To facilitate medical countermeasure development, we determined a 3.5-angstrom

156 ivities has escalated the need for radiation countermeasure development.

157 esponses and protective effects of radiation countermeasure drugs, whereas conventional bone marrow c

158 An urgent need for countermeasures during this crisis challenges the curren

159 owsiness by engaging in multiple ineffective countermeasures (e.g., listening to music) and effective

160 res (e.g., listening to music) and effective countermeasures (e.g., naps) were used sparingly.

161 produce more potent active vaccines, passive countermeasures (e.g., Tc bovine), and as a means to pro

162 The development and testing of new medical countermeasures, e.g., vaccines, are thus priorities; ho

163 e antiviral role of ISG15 conjugation and on countermeasures employed by several viruses.

164 man Services Public Health Emergency Medical Countermeasures Enterprise.

165 man Services Public Health Emergency Medical Countermeasures Enterprise.

166 man Services Public Health Emergency Medical Countermeasures Enterprise.

167 ever and arthritis in multiple countries, no countermeasures exist against Mayaro virus (MAYV), an em

168 able throughout life, implying that adaptive countermeasures exist that maintain neurotransmission wi

169 epidemics and for which no, or insufficient countermeasures exist.

170 dy treatment is currently the only available countermeasure for botulism, a fatal illness caused by f

171 on of TRAIL expression could be an effective countermeasure for muXg induced bone loss.

172 , Uber has been characterized as a potential countermeasure for reducing the estimated 121 million ep

173 across tissues, is emerging as an effective countermeasure for sarcopenia.

174 used prophylactically or therapeutically as countermeasures for a variety of infectious diseases.

175 d and it is imperative to identify potential countermeasures for acute radiation syndrome.

176 eatment, and health education are the common countermeasures for controlling the disease.

177 , there is an urgent need to develop medical countermeasures for disease prevention and treatment.

178 Developing effective countermeasures for drowsy driving in nurses requires a

179 strategies are being developed as promising countermeasures for influenza virus infections.

180 icating possible sex-specific mechanisms and countermeasures for obesity in male and female shift wor

181 g the pathogenesis of and evaluating medical countermeasures for persisting Middle East respiratory s

182 dvance the understanding of the use of these countermeasures for post-exposure prophylaxis against Eb

183 elopment and selection of the most effective countermeasures for prophylactic as well as therapeutic

184 use and nerve agents holds promise for rapid countermeasures for protecting soldiers, civilians, and

185 In an effort to engineer countermeasures for the category B toxin ricin, we produ

186 Nutritional countermeasures for the prevention of poor iron status a

187 vailable, progress in preclinical testing of countermeasures has been made.

188 To solve this problem, numerous methods of countermeasure have been proposed.

189 Currently no countermeasures have been approved for prophylactic admi

190 As a countermeasure, HIV-1 viral infectivity factor (Vif) bin

191 nc) and R(con), an index of effectiveness of countermeasures (I(eff)) was developed to assess the eff

192 ort has been dedicated to the development of countermeasures, implementation of these countermeasures

193 portance for the evolution of virus-employed countermeasures.IMPORTANCE Cytomegalovirus (a betaherpes

194 data reveal that MSCs could be an effective countermeasure in cancer patients and victims of nuclear

195 g pressure in the brain holds potential as a countermeasure in space as well as having treatment pote

196 sed oil and dispersants used as an oil spill countermeasure in the Gulf of Mexico.

197 r speculated attack capabilities can argue a countermeasure in, but no possible observation argues on

198 e) heavy-ion exposures and the validation of countermeasures in a relevant space environment.

199 was developed to assess the effectiveness of countermeasures in each outbreak.

200 rt is under way to facilitate the testing of countermeasures in infectious disease emergencies.

201 of countermeasures, implementation of these countermeasures in nursing has lagged behind other shift

202 must suppress or evade an array of host cell countermeasures in order to establish a productive infec

203 virulence factors and targets for developing countermeasures in pathogenic Gram-negative bacteria.

204 celerate the development of specific medical countermeasures in preparation for a future disease outb

205 ecologies of key predators will reveal such countermeasures in prey.

206 and for implementation of effective medical countermeasures, in case a "biological cloud" is seen ov

207 Bacterial countermeasures include the up-regulation of copper expo

208 Given current countermeasures including in-flight exercise training an

209 uld render current molecular diagnostics and countermeasures ineffective.

210 As a countermeasure, infected cell protein 0 (ICP0) of herpes

211 ls.IMPORTANCE The development of Ebola virus countermeasures is challenged by our limited understandi

212 y have unanticipated activities as potential countermeasures is one way to meet this important goal,

213 An anticipated correlate of such countermeasures is the level of neutralizing antibodies

214 To develop effective medical countermeasures, it is important to understand the impor

215 ombined with the paucity of licensed medical countermeasures makes EBOV a critical human pathogen.

216 Licensure of any medical countermeasure may require demonstration of efficacy in

217 demonstrate that promising candidate medical countermeasures may not completely clear EBOV infection.

218 are sometimes harmful to females, and female countermeasures may thwart the interests of males, which

219 To date, no approved medical countermeasures (MCM) are available to combat MERS-CoV i

220 here is an immediate need to develop medical countermeasures (MCMs) to combat irradiation-induced let

221 genesis and development of effective medical countermeasures (MCMs) urgent.

222 present there are no Ebola-specific medical countermeasures (MCMs) with proven effectiveness.

223 As a countermeasure, members of the genus Begomovirus (e.g.,

224 As a countermeasure, numerous phages are known that produce p

225 into the role of cellular miRNAs in possible countermeasures of HCV for suppression of the host antiv

226 igated the tetherin sensitivity and possible countermeasures of herpes simplex virus 1 (HSV-1).

227 ame sensitivity to nondegradative lentiviral countermeasures of HIV-2 and SIVmac, respectively.

228 olved to replicate and to overcome antiviral countermeasures of the infected cell.

229 Whether host autophagic responses and viral countermeasures play similar roles in plant-virus intera

230 xty years, NASA developed a state-of-the-art countermeasures program (CMP) to characterize and mitiga

231 overy posts a challenge to develop effective countermeasures, provides a novel tool for studying intr

232 Development of appropriate medical countermeasures requires a thorough understanding of the

233 Recent advances in medical countermeasure research resulted in the recent approval

234 at began in late 2013, the lack of effective countermeasures resulted in chains of serial infection a

235 Effective countermeasures should function to increase survival in

236 The lack of efficient countermeasure strategies, the potential for dispersion

237 decoding validity may be the deployment of "countermeasures": strategies used to mask memory signals

238 binding to the host receptor is an efficient countermeasure strategy.

239 e addressed by efficient, quickly deployable countermeasures such as antidotes reactivating acetylcho

240 We show that countermeasures such as hiding certain parts of the geno

241 Development of effective countermeasures, such as therapeutics and an effective v

242 Here we show that unlike other virus-encoded countermeasures, such as those from primate viruses rela

243 scade lasers in applications such as optical countermeasure systems and secure atmospheric transmissi

244 Antibody-based countermeasures targeting the ZIKV envelope protein have

245 ductive virus infection often requires viral countermeasures that block innate immunity.

246 sistance to CHIKV infection could facilitate countermeasures that disrupt Mxra8 interactions with alp

247 However, viruses have evolved countermeasures that prevent the epigenetic silencing of

248 LPS sensing mechanisms and discuss bacterial countermeasures that promote infection.

249 employ to prevent rotavirus invasion and the countermeasures that these viruses have successfully dev

250 ion in the GEDmatch database, and we suggest countermeasures that will prevent the exploits we descri

251 As a countermeasure, the viral ICP34.5 polypeptide, which is

252 for the deployment of a stockpiled radiation countermeasure to a radiation mass casualty site, there

253 d effectiveness and potency as a therapeutic countermeasure to antigenically diverse ebolaviruses.

254 findings identify AFSC transplantation as a countermeasure to bone fragility.

255 l MK-4482/EIDD-2801 as a promising antiviral countermeasure to break SARS-CoV-2 community transmissio

256 in recent years as a potential prophylactic countermeasure to decrease the prevalence of hospital-ac

257 the final stage of pursuit, presumably as a countermeasure to keep evading moths within their "acous

258 data suggest that captopril may be an ideal countermeasure to mitigate H-ARS following accidental ra

259 e that the ICP0-PML.I interaction reflects a countermeasure to PML-related antiviral restriction.

260 HCMV then activates cellular autophagy as a countermeasure to prevent the execution of necroptosis,

261 equate protein is consumed at each meal as a countermeasure to sarcopenia are presented and discussed

262 itoes with Wolbachia bacteria offers a novel countermeasure to suppress DENV transmission, but the me

263 nance of bone health and may be an effective countermeasure to weight-loss-associated bone loss.

264 rapid development and evaluation of medical countermeasures to address the ongoing public health cri

265 o a mitochondrial toxin, revealing bacterial countermeasures to animal defence.

266 n the treatment of disease but also serve as countermeasures to biological warfare.

267 er pathogenesis as well as designing vaccine countermeasures to C. burnetii aerosol transmission.

268 eakness is essential to developing effective countermeasures to combat this important problem.

269 asion strategies of FMDV may help to develop countermeasures to control FMDV infections in the future

270 uman health, there are currently no approved countermeasures to control infections with these viruses

271 ggest that GraS mediates specific resistance countermeasures to HDPs in immune contexts that are high

272 The Herpesviridae have evolved countermeasures to IFN responses.

273 irtually all pathogenic viruses have evolved countermeasures to IFN-I restriction, and genetic loss o

274 irus encodes several factors that limit host countermeasures to infection, including pp71.

275 ases upstream of STAT5, suggesting divergent countermeasures to inhibit STAT5 activation.

276 world settings, and lastly discuss potential countermeasures to lessen the impact of sleep inertia.

277 , if any, dsRNA or that more efficient viral countermeasures to mask dsRNA are mounted.

278 viral replication, and viruses have evolved countermeasures to neutralize them.

279 In crafting countermeasures to offset this, it is important to know

280 eted pharmacological and non-pharmacological countermeasures to optimize performance that are mission

281 Countermeasures to prevent and treat coronavirus disease

282 Based on the proposed reaction mechanisms, countermeasures to prevent Cr oxidation (addition of NH4

283 tion and for the initial phase of developing countermeasures to prevent or treat viral infections.

284 hasise the need for development of effective countermeasures to promote sleep.

285 tes has increased efforts to develop medical countermeasures to protect against radiation toxicities

286 Thus, it is desirable to have countermeasures to reverse a drive if a problem arises.

287 hosts have developed a variety of metabolic countermeasures to sense and resist these viral changes.

288 ron-mediated antiviral defenses and by viral countermeasures to these defenses.

289 sessing xenobiotic exposure and as potential countermeasures to toxicity.

290 or the development and evaluation of medical countermeasures to treat and prevent Lassa fever, such a

291 iviruses can inform the rapid development of countermeasures to treat or prevent human infections as

292 nce could help to develop safe and effective countermeasures to treat ZIKV or to prevent future outbr

293 Adaptation remains the most effective countermeasure together with established medications, no

294 being essential for controlling host defense countermeasures triggered by microbial cytosolic DNA and

295 oprotective efficacy of amifostine and other countermeasures under development.

296 n have shaped both the immune system and the countermeasures used by pathogens.

297 nerability of fMRI-based memory detection to countermeasures, using a paradigm that bears resemblance

298 continued investments in the development of countermeasures (vaccines, therapeutic agents, and diagn

299 at the beginning of the epidemic no licensed countermeasures were available, several experimental dru

300 The most commonly implemented countermeasures were case isolation, treatment, and heal